&lt;p&gt;Ribosome Binding Protein 1 Correlates with Prognosis and Cell Proliferation in Bladder Cancer&lt;/p&gt;

Lv, Shuang-wu; Shi, Zhiyuan; Wang, Xiaohui; Zheng, Pengyi; Li, Huibing; Han, Qingjiang; Li, Zhijun

doi:10.2147/ott.s252043

Cited by 5 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Forty-eight hours after transfection of the shRRBP1 plasmid targeting BFTC909, both mRNA and protein expression levels were inhibited (Figure 4F). RRBP1 was previously associated with cell proliferation [35]. In the present study, WST-1 analysis performed 48 h after transfection of shRRBP1 with BFTC909 showed that RRBP1 was inhibited and cell proliferation was reduced (Figure 4H).…”

Section: Rrbp1 Is Highly Expressed In Utuc Tumor Tissues and Cancer Cell Lines Of Urothelial Tumorssupporting

confidence: 66%

See 1 more Smart Citation

Hypomethylated RRBP1 Potentiates Tumor Malignancy and Chemoresistance in Upper Tract Urothelial Carcinoma

Luo

Liu

Chang

et al. 2021

IJMS

View full text Add to dashboard Cite

Ribosome-binding protein 1 (RRBP1) is a potential oncogene in several cancer types. However, the correlation between RRBP1 expression and the prognosis of patients with upper tract urothelial carcinoma (UTUC) remains unclear. In this study, we identified that RRBP1 is associated with carcinogenesis and metastasis in UTUC using a methylation profiling microarray. High correlations between RRBP1 and cancer stages, nodal metastasis status, molecular subtypes, and prognosis in bladder urothelial cancer (BLCA) were found. Aberrant DNA methylation in the gene body region of RRBP1 was determined in UTUC tissues by methylation-specific PCR. RRBP1 expression was significantly increased in UTUC tissues and cell lines, as determined by real-time PCR and immunohistochemistry. RRBP1 depletion significantly reduced BFTC909 cell growth induced by specific shRNA. On the other hand, molecular subtype analysis showed that the expression of RRBP1 was associated with genes related to cell proliferation, epithelial–mesenchymal transition, and basal markers. A patient-derived organoid model was established to analyze patients’ responses to different drugs. The expression of RRBP1 was related to chemoresistance. Taken together, these results provide the first evidence that RRBP1 gene body hypomethylation predicts RRBP1 high expression in UTUC. The data highlight the importance of RRBP1 in UTUC malignancy and chemotherapeutic tolerance.

show abstract

Section: Rrbp1 Is Highly Expressed In Utuc Tumor Tissues and Cancer Cell Lines Of Urothelial Tumorssupporting

confidence: 66%

“…The upregulated expression of RRBP1 in lung cancer, colorectal cancer, endometrial endometrioid adenocarcinoma, ovarian, breast, and bladder cancer leads to poor prognosis [22,26,29,30,35,40]. The inhibited expression of RRBP1 could potentially reduce the proliferation and metastasis of cancer cell lines.…”

Section: Discussionmentioning

confidence: 99%

Hypomethylated RRBP1 Potentiates Tumor Malignancy and Chemoresistance in Upper Tract Urothelial Carcinoma

Luo

Liu

Chang

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…In our patient, two ALK fusion partners ( RRBP1 , HAO1 ) were detected simultaneously by RNA-seq. RRBP1 is an ER membrane protein in the secretion and transportation of nascent proteins in mammalian cells ( 8 ). RRBP1 overexpression has been confirmed to be associated with poor prognosis and an independent predictor of overall survival (OS) and disease-free survival (DFS) in other cancers, for example, epithelial ovarian cancer ( 9 ).…”

Section: Discussionmentioning

confidence: 99%

“…RRBP1 overexpression has been confirmed to be associated with poor prognosis and an independent predictor of overall survival (OS) and disease-free survival (DFS) in other cancers, for example, epithelial ovarian cancer ( 9 ). It is due to that RRBP1 overexpression can promote tumor cell proliferation ( 8 ). In our case, the 3' end of ALK exon 19 fused to the 5' end of RRBP1 exon 10.…”

Section: Discussionmentioning

confidence: 99%

A recurrent inflammatory myofibroblastic tumor patient with two novel ALK fusions: a case report

Xu¹,

Li²,

Zhang³

et al. 2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Inflammatory myofibroblastic tumor (IMT) is a rare disease that mainly involves the lung and the abdomen. The gold standard of the IMT treatment is radical surgery, while chemotherapy and radiotherapy are represented usually for unresectable lesions. Anaplastic lymphoma kinase (ALK) rearrangements are present in approximately 50% of IMT patients, and several clinical trials of ALK tyrosine kinase inhibitors (TKIs) in the treatment of ALK-positive IMT patients are underway.Case Description: We reported a case of IMT in the right pelvic cavity. Initially, the patient underwent resection of multiple lesions. Unfortunately, the patient's tumor recurred half a year later, and enhanced computerized tomography (CT) of the whole abdomen revealed multiple low-density masses. Then the patient underwent resection of the recurrent tumors. Immunohistochemical staining exhibited the expression of ALK in the tumor cells, and next-generation sequencing (NGS) technology revealed two novel ALK fusions, ALK-ribosome binding protein 1 (RRBP1) and hydroxyacid oxidase 1 (HAO1)-ALK fusions. These fusions were able to be transcribed and captured by RNA level. And the two fusions have not been reported in the IMTs.Conclusions: This case expanded the range of ALK fusion types and provided a promising moleculartargeted treatment strategy. In addition, the two novel ALK fusions may be the recurrent oncogenic mechanism in clinically aggressive IMT.

show abstract

“…Recently, RRBP1 has been identified as an important oncogenic factor to induce tumorigenesis and malignant progression. RRBP1 is reported to be highly expressed in multiple cancers and may serve as a potential biomarker for prognostic prediction [ 27 , 28 , 29 , 32 , 47 , 48 ]. Although several studies have shown that the enhanced RRBP1 expression in tumor cells is attributed to its transcriptional and translational activation [ 49 , 50 , 51 ], nothing is known about whether RRBP1 can be regulated at post‐translational level.…”

Section: Discussionmentioning

confidence: 99%

USP35 mitigates endoplasmic reticulum stress‐induced apoptosis by stabilizing RRBP1 in non‐small cell lung cancer

Wang

Wang²,

Xiao

et al. 2021

Molecular Oncology

View full text Add to dashboard Cite

Deubiquitinating enzymes (DUBs) serve to maintain cellular homeostasis via protein ubiquitination and exert diverse regulatory functions in cancers and other diseases. Much progress has been made in characterizing biological roles of DUBs over the decades, yet the specific functions of many subclass members remain largely unexplored. It was not until recent years that the role of ubiquitin-specific-processing protease 35 (USP35) in cancers began to be understood. Here, we focus on delineating the roles and underlying mechanisms of USP35 in non-small cell lung cancer (NSCLC). The isobaric tags for relative and absolute quantitation (iTRAQ) comparative proteomic approach were employed to identify differentially expressed proteins (DEPs) in H1299 cells induced by USP35 overexpression or silencing. Among the potential interactome of USP35, ribosome-binding protein 1 (RRBP1), a membrane-bound protein in endoplasmic reticulum (ER), captured our attentions. RRBP1 expression was found to positively correlate with USP35 levels in both genetically modified cells and human NSCLC tissues. Concordantly, both RRBP1 expression and USP35 expression were found to positively correlate with poor prognoses in lung adenocarcinoma patients. At the molecular level, USP35 was verified to directly interact with RRBP1 to prevent it from proteasomal-dependent degradation. Functionally, USP35 alleviated ER stress-induced cell apoptosis by stabilizing RRBP1 in NSCLC cells. Collectively, these findings indicate that USP35 plays a critical role in resisting ER stress-induced cell death through deubiquitinating RRBP1, hence providing a rationale to target the USP35-RRBP1 axis as an alternative therapeutic option for NSCLC.

show abstract

<p>Ribosome Binding Protein 1 Correlates with Prognosis and Cell Proliferation in Bladder Cancer</p>

Cited by 5 publications

References 30 publications

Hypomethylated RRBP1 Potentiates Tumor Malignancy and Chemoresistance in Upper Tract Urothelial Carcinoma

Hypomethylated RRBP1 Potentiates Tumor Malignancy and Chemoresistance in Upper Tract Urothelial Carcinoma

A recurrent inflammatory myofibroblastic tumor patient with two novel ALK fusions: a case report

USP35 mitigates endoplasmic reticulum stress‐induced apoptosis by stabilizing RRBP1 in non‐small cell lung cancer

Contact Info

Product

Resources

About